Paul Blake. Insider Profile

4 Followers
Paul Blake., Chief Development Officer at Oxford BioMedica, holds 2.62M shares in Oxford BioMedica (Ticker: OXBDF), holds 70.35K shares in COSCIENS Biopharma (Ticker: CSCI). Most recently, Paul Blake. Bought ― shares of Oxford BioMedica on Mar 16, 2015 for an estimated value of 10.00K.
tipranks
Paul Blake.

Paul Blake.
Oxford BioMedica (OXBDF)
Chief Development Officer

Ranked #2,022 out of 99,218 Corporate Insiders

Profitable Transactions

80%
4 out of 5 Profitable Transactions

Average Return

+115.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$15M
98.38%
1.62%
A breakdown of Paul Blake.'s holdings

Insider Roles

Oxford BioMedica
(OXBDF)
Chief Development Officer
COSCIENS Biopharma
(CSCI)
Former
Roles that Paul Blake. holds in companies

Most Profitable Insider Trade

Stock:
Oxford BioMedica
(OXBDF)
Rating:Informative Buy
Date:Jul 01, 2014 - Jul 01, 2015
Return:+267.50%
The most profitable trade made by Paul Blake.

Paul Blake.'s Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Oxford BioMedica
Mar 16, 2015
Chief Development Officer
Informative Buy
10.00K
$14.30M
COSCIENS Biopharma
Former
$235.67K
List of latest transactions for each holding click on a transaction to see Paul Blake.'s performance on stock

Paul Blake. insider profile FAQ

What is the percentage of profitable transactions made by Paul Blake.?
The percentage of profitable transactions made by Paul Blake. is 80%.
    What is the average return per transaction made by Paul Blake.?
    The average return per transaction made by Paul Blake. is 115.90%.
      What stocks does Paul Blake. hold?
      Paul Blake. holds: OXBDF, CSCI stocks.
        What was Paul Blake.’s latest transaction?
        Paul Blake. latest transaction was an Informative Buy of $10.00K.
          What was Paul Blake.'s most profitable transaction?
          Paul Blake.’s most profitable transaction was an Informative Buy of OXBDF stock on July 1, 2014. The return on the trade was 267.50%.
            What is Paul Blake.'s role in Oxford BioMedica?
            Paul Blake.'s role in Oxford BioMedica is Chief Development Officer.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.